Syntropic Medical funding news – Vienna-based Syntropic Medical Secures €1.1 Million in Funding
Jul 23, 2024 | By Startup Rise EU
![Medtech company Syntropic Medical, secures €1.1 million in funding from The Austrian Research Promotion Agency (FFG) for its light-based brain stimulation device to treat drug-resistant neuropsychiatric disorders such as major depressive disorder.](https://startuprise.co.uk/wp-content/uploads/2024/07/Vienna-based-Syntropic-Medical-Secures-E1.1-Million-in-Funding-.webp)
Medtech company Syntropic Medical, secures €1.1 million in funding from The Austrian Research Promotion Agency (FFG) for its light-based brain stimulation device to treat drug-resistant neuropsychiatric disorders such as major depressive disorder.
SUMMARY
- Medtech company Syntropic Medical, secures €1.1 million in funding from The Austrian Research Promotion Agency (FFG) for its light-based brain stimulation device to treat drug-resistant neuropsychiatric disorders such as major depressive disorder.
- Syntropic is a medical device firm in the pre-clinical stage that is creating new technologies to boost neuroplasticity in the brain, which can be used to treat mental illnesses and improve cognitive function.
The business was founded by Prof. Sandra Siegert, Dr. Alessandro Venturino, Jack O'Keeffe, and Mark Caffrey and was spun out of the Institute of Science and Technology Austria (ISTA).
Read Also - Nscale Acquisition News -Nscale Acquires Kontena to Enhance HPC and AI Infrastructure Capabilities
The Siegert Group at ISTA developed a light stimulation protocol that serves as the foundation for Syntropic's innovative light-based brain stimulation device. By stimulating the brain in a way that encourages microglia-mediated neuroplasticity, they can potentially cure a variety of neuropsychiatric conditions, including Major Depressive Disorder (MDD). By doing this, Syntropic hopes to give patients who have not responded adequately to conventional pharmaceutical medicines an alternative course of treatment.
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2023/11/Lithuania-based-Green-Energy-Company-Green-Genius-Secures-E6.9M-in-Funding.webp)
[Funding alert] Lithuania-based Green Energy Company Green Genius Secures €6.9M in Funding
Startup Rise EU
Nov 1, 2023
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/02/Switzerland-based-Spiden-Secures-15Million-in-Additional-Funding.webp)
[Funding alert] Switzerland-based Spiden Secures $15Million in Additional Funding
Startup Rise EU
Feb 1, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/05/Fintech-Startup-Birdwingo-Secures-E1.2-Million-in-Funding.webp)
Birdwingo funding news – Fintech-Startup Birdwingo Secures €1.2 Million in Funding
Startup Rise EU
May 3, 2024
Mark Caffrey, Syntropic CEO said, “Approximately 70 per cent of patients taking pharmaceutical antidepressants will fail to achieve remission, and up to 25 per cent will stop taking them due to the severity of side effects. These numbers are unfortunately not good enough. Therefore, it is crucial that we begin to develop completely new methods of tackling these disorders. This is why the discoveries of Dr Venturino and Prof Siegert are so exciting, they open the potential for an entirely new modality of treatment that is side effect free and easily accessible for the patient,”.
About Syntropic
Syntropic is a medical device firm in the pre-clinical stage that is creating new technologies to boost neuroplasticity in the brain, which can be used to treat mental illnesses and improve cognitive function.